A Brief History of Nabriva Therapeutics plc (NBRV)

Nabriva Therapeutics plc is a biopharmaceutical company focused on the development and commercialization of novel antibiotics to treat serious infections. The company was founded in 2005 and is headquartered in Dublin, Ireland.

• 2005: Nabriva Therapeutics was founded with the mission to address the growing problem of antibiotic resistance by developing new and innovative treatments for bacterial infections.
• 2006: The company focused its research and development efforts on a class of antibiotics known as pleuromutilins, which have demonstrated potent activity against a wide range of bacteria, including drug-resistant strains.
• 2015: Nabriva Therapeutics went public, trading on the NASDAQ under the ticker symbol NBRV. This provided the company with additional funding to support its clinical development programs.
• 2017: Nabriva Therapeutics received approval from the U.S. Food and Drug Administration (FDA) for its first commercial product, Xenleta (lefamulin), for the treatment of community-acquired bacterial pneumonia (CABP) in adults.
• 2020: The company continued to advance its pipeline of antibiotics, with several drugs in various stages of development for the treatment of skin infections, urinary tract infections, and other serious bacterial infections.

• One of the largest institutional investors in Nabriva Therapeutics plc is BlackRock, Inc., with a significant ownership stake in the company.
• Other notable institutional investors include Vanguard Group, Inc. and Fidelity Management & Research Company LLC.
• Individual stakeholders in Nabriva Therapeutics plc include company executives, board members, and individual investors who have purchased shares through public markets or private placements.

Overall, the ownership structure of Nabriva Therapeutics plc is diversified, with a combination of institutional and individual investors holding significant stakes in the company. This mix of ownership helps to ensure a broad base of support and interest in the company's success.

Nabriva Therapeutics plc (NBRV) Mission Statement

At Nabriva Therapeutics plc, our mission is to deliver innovative anti-infective agents to address the global public health crisis of antibiotic resistance. We are committed to developing and commercializing novel antibiotics to treat serious infections, with a focus on pathogens that have developed resistance to current treatment options.

Our goal is to provide healthcare providers with new and effective tools to combat drug-resistant infections, improving patient outcomes and reducing the spread of antibiotic-resistant bacteria.

Through research and development initiatives, we strive to discover and bring to market new therapies that target unmet medical needs in the field of infectious diseases. We are dedicated to advancing the science of antibiotic development and promoting responsible antibiotic use to preserve the efficacy of these life-saving drugs for future generations.

• Innovation: We are committed to advancing the field of anti-infective agents through innovative research and development.
• Patient Care: Our ultimate goal is to improve patient outcomes by providing effective treatments for serious infections.
• Antibiotic Stewardship: We promote responsible antibiotic use to combat the rise of drug-resistant bacteria.
• Global Impact: We strive to address the public health crisis of antibiotic resistance on a global scale, providing solutions for healthcare providers worldwide.

How Nabriva Therapeutics plc (NBRV) Works

Nabriva Therapeutics plc is a biopharmaceutical company focused on the research and development of novel anti-infective agents to treat serious infections. The company's mission is to address the growing problem of antibiotic resistance by developing new treatment options for patients.

One of the key strategies employed by Nabriva Therapeutics is to focus on the development of antibiotics that target specific types of bacteria. By targeting specific pathogens, the company aims to reduce the risk of resistance developing and improve treatment outcomes for patients.

Nabriva Therapeutics also collaborates with academic institutions, research organizations, and other biopharmaceutical companies to advance its pipeline of antibiotic treatments. These collaborations allow the company to leverage the expertise of leading researchers and scientists in the field of infectious diseases.

• Research and Development: Nabriva Therapeutics invests heavily in research and development to discover and develop new antibiotic therapies. The company's pipeline includes both early-stage and late-stage compounds targeting a range of bacterial infections.
• Clinical Trials: Nabriva Therapeutics conducts clinical trials to evaluate the safety and efficacy of its antibiotic candidates. These trials are essential for obtaining regulatory approval and bringing new treatments to market.
• Regulatory Approval: Once clinical trials are completed, Nabriva Therapeutics seeks regulatory approval from health authorities such as the FDA and EMA. This approval is necessary to market and sell its antibiotic treatments to healthcare providers and patients.
• Commercialization: Upon receiving regulatory approval, Nabriva Therapeutics works to commercialize its antibiotic products through partnerships with pharmaceutical companies, distributors, and healthcare providers. This ensures that patients have access to the company's novel treatments.

How Nabriva Therapeutics plc (NBRV) Makes Money

Nabriva Therapeutics plc is a biopharmaceutical company focused on the development and commercialization of novel antibiotics to treat serious infections. The company generates revenue through the following key ways:

• Product Sales: Nabriva generates revenue from the sale of its products, such as its flagship antibiotic drug XENLETA (lefamulin), which is used to treat community-acquired bacterial pneumonia. Sales of this product contribute significantly to the company's revenue stream.
• Licensing Agreements: Nabriva also earns revenue through licensing agreements with other pharmaceutical companies. These agreements typically involve the development and commercialization of new antibiotic drugs, with Nabriva receiving upfront payments, milestone payments, and royalties on future sales.
• Research and Development Grants: The company also receives funding from research and development grants, which help support the development of its pipeline of antibiotic drugs. These grants are typically provided by government agencies, nonprofit organizations, and other entities interested in advancing the field of antibiotic research.
• Strategic Partnerships: Nabriva enters into strategic partnerships with other companies in the pharmaceutical industry to co-develop and co-commercialize new antibiotic drugs. These partnerships often involve revenue-sharing agreements and upfront payments that help support the company's research and development efforts.